Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
Open Access
- 17 August 2023
- journal article
- research article
- Published by BMJ in Open Heart
- Vol. 10 (2) , e002301
Abstract
Background Tocilizumab improves myocardial salvage index (MSI) in patients with ST-elevation myocardial infarction (STEMI), but its mechanisms of action are unclear. Here, we explored how cytokines were affected by tocilizumab and their correlations with neutrophils, C-reactive protein (CRP), troponin T, MSI and infarct size. Methods STEMI patients were randomised to receive a single dose of 280 mg tocilizumab (n=101) or placebo (n=98) before percutaneous coronary intervention. Blood samples were collected before infusion of tocilizumab or placebo at baseline, during follow-up at 24–36, 72–168 hours, 3 and 6 months. 27 cytokines were analysed using a multiplex cytokine assay. Cardiac MRI was performed during hospitalisation and 6 months. Results Repeated measures analysis of variance showed significant (pConclusions Tocilizumab increases IL-6, IL-8 and IL-1ra in STEMI. IL-6 and IL-8 show correlations to neutrophils/CRP and markers of cardiac injury in the placebo group that was attenuated in the tocilizumab group. This may suggest a beneficial effect of tocilizumab on the ischaemia-reperfusion injury in STEMI patients. Trial registration number NCT03004703.Keywords
Funding Information
- Roche
- Central Norway Regional Health Authority
- South-Eastern Norway Regional Health Authority
This publication has 27 references indexed in Scilit:
- Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trialEuropean Heart Journal, 2016
- Protective function of tocilizumab in human cardiac myocytes ischemia reperfusion injuryAsian Pacific Journal of Tropical Medicine, 2015
- C-reactive protein as a predictor of adverse outcome in patients with acute coronary syndromeHeart Views, 2012
- Design and validation of Segment - freely available software for cardiovascular image analysisBMC Medical Imaging, 2010
- Inflammatory markers and cardiac function in acute coronary syndrome: Difference in ST-segment elevation myocardial infarction (STEMI) and in non-STEMI modelsBiomedicine & Pharmacotherapy, 2009
- TocilizumabDrugs, 2009
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate RiskJACC, 2007
- Cardiac Interleukin-6 in Ischemic MyocardiumCirculation, 2000